Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Contingent consideration valuation by Quarter
Contingent consideration valuation — Discount rate range maximum (%) (%)
Vertex Pharmaceuticals Contingent consideration valuation: 470.0% in Q2 2026, up 10.0 pts from a year earlier.
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-04) ↗
Reported in Form 10-Q / 10-K Fair Value Measurements Note.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Contingent consideration valuation — Discount rate range maximum (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 470.0% | +10.0 pts | Form 10-Q (filed 2026-08-04) ↗ |
| Q1 2026 | Mar 31, 2026 | 460.0% | 0.0 pts | Form 10-Q (filed 2026-05-05) ↗ |
| Q4 2025 | Dec 31, 2025 | 450.0% | -60.0 pts | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2025 | Sep 30, 2025 | 450.0% | +10.0 pts | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2025 | Jun 30, 2025 | 460.0% | -100.0 pts | Form 10-Q (filed 2025-08-05) ↗ |
| Q1 2025 | Mar 31, 2025 | 460.0% | -70.0 pts | Form 10-Q (filed 2025-05-06) ↗ |
| Q4 2024 | Dec 31, 2024 | 510.0% | +20.0 pts | Form 10-K (filed 2025-02-13) ↗ |
| Q3 2024 | Sep 30, 2024 | 440.0% | -210.0 pts | Form 10-Q (filed 2024-11-05) ↗ |
| Q2 2024 | Jun 30, 2024 | 560.0% | -90.0 pts | Form 10-Q (filed 2024-08-02) ↗ |
| Q1 2024 | Mar 31, 2024 | 530.0% | -50.0 pts | Form 10-Q (filed 2024-05-07) ↗ |
| Q4 2023 | Dec 31, 2023 | 490.0% | -110.0 pts | Form 10-K (filed 2024-02-15) ↗ |
| Q3 2023 | Sep 30, 2023 | 650.0% | +80.0 pts | Form 10-Q (filed 2023-11-07) ↗ |
| Q2 2023 | Jun 30, 2023 | 650.0% | +230.0 pts | Form 10-Q (filed 2023-08-02) ↗ |
| Q1 2023 | Mar 31, 2023 | 580.0% | +250.0 pts | Form 10-Q (filed 2023-05-02) ↗ |
| Q4 2022 | Dec 31, 2022 | 600.0% | +370.0 pts | Form 10-K (filed 2023-02-10) ↗ |
| Q3 2022 | Sep 30, 2022 | 570.0% | +350.0 pts | Form 10-Q (filed 2022-10-28) ↗ |
| Q2 2022 | Jun 30, 2022 | 420.0% | +200.0 pts | Form 10-Q (filed 2022-08-05) ↗ |
| Q1 2022 | Mar 31, 2022 | 330.0% | +90.0 pts | Form 10-Q (filed 2022-05-06) ↗ |
| Q4 2021 | Dec 31, 2021 | 230.0% | +40.0 pts | Form 10-K (filed 2022-02-09) ↗ |
| Q3 2021 | Sep 30, 2021 | 220.0% | +30.0 pts | Form 10-Q (filed 2021-11-03) ↗ |
| Q2 2021 | Jun 30, 2021 | 220.0% | +20.0 pts | Form 10-Q (filed 2021-07-30) ↗ |
| Q1 2021 | Mar 31, 2021 | 240.0% | -70.0 pts | Form 10-Q (filed 2021-04-30) ↗ |
| Q4 2020 | Dec 31, 2020 | 190.0% | – | Form 10-K (filed 2021-02-11) ↗ |
| Q3 2020 | Sep 30, 2020 | 190.0% | – | Form 10-Q (filed 2020-10-30) ↗ |
| Q2 2020 | Jun 30, 2020 | 200.0% | – | Form 10-Q (filed 2020-07-31) ↗ |
| Q1 2020 | Mar 31, 2020 | 310.0% | – | Form 10-Q (filed 2020-05-01) ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals Contingent consideration valuation (%), quarterly Q1 2020–Q2 2026 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/cc-disc-rate-max
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.